Non-invasive assessment of swallowing and respiration in Parkinson's disease.

Oro-pharyngeal dysphagia is well recognised but often underestimated in people with Parkinson's disease. Asymptomatic patients may fail to receive timely advice or therapy, thus placing them at risk. The aim of this study was to determine whether subclinical abnormalities in swallowing and discrete changes in function such as those produced by prompting can be detected by non-invasive methods. We examined 12 people with idiopathic Parkinson's disease and 14 elderly comparison subjects. Five components of respiratory synchronisation and swallowing efficiency were monitored using the Exeter Dysphagia Assessment Technique. Ten feeding trials were administered under standard quiet conditions. The patients were then restudied using verbal prompts when the spoon was presented to the mouth. The duration of two oro-pharyngeal events and the frequency of respiratory variables were compared for unrelated and related samples. Results showed the oral and pharyngeal parts of the swallow to be significantly slower in those with Parkinson's disease. These patients required significantly more swallows to clear a 5-ml bolus, and fewer swallows were followed by expiration. When the patients were verbally prompted, there was a significant reduction in the duration of the oral part. This study demonstrates that non-invasive methods can be used to detect subclinical difficulties with swallowing amongst a group of asymptomatic patients with PD and that these methods are sensitive to small changes in function produced by a verbal cue.

Interrater and intrarrater reliability of the exeter dysphagia assessment technique applied to healthy elderly adults.

The purpose of this study was to evaluate the inter- and intrarater reliabilities of the Exeter Dysphagia Assessment Technique in a sample of elderly adults. This procedure uses noninvasive methods to record aspects of oral motor efficiency and synchronization of respiration during swallowing with the aid of specially developed equipment. Changes in the direction of nasal air flow, time of lip or tongue/spoon contact, and the time/frequency of swallow sounds are monitored and analyzed. Seventy records were evaluated independently by three trained assessors on three consecutive occasions. Interrater reliability was found to be good to very good for five of the respiratory variables assessed and moderate for the sixth. Interrater agreement was also very good for three of the timed oropharyngeal events assessed and moderate for the fourth. Intrarater reliability was very good for the same five respiratory variables and moderate for the sixth. Intrarater agreement was also very good for three of the timed oropharyngeal events and moderate for the fourth. Repeat evaluations of these records showed that agreement between and within raters concerning the sixth respiratory variable was improved substantially when the charts were examined in an enlarged form that provided improved resolution. We conclude that the majority of variables monitored by the Exeter Dysphagia Assessment Technique can be evaluated very reliably.

The use of capsaicin cream in a case of erythromelalgia.

We present a case of erythromelalgia in a 68 year old lady who responded, within 48 hours, to a twice daily topical application of capsaicin cream 0.025%. Capsaicin cream was stopped after 2 months, and 6 months later the patient continued to have the symptomatic relief she experienced initially.

Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?

Apomorphine is a potent dopamine agonist at both D1 and D2 receptors and has been used successfully for treating the 'on/off' phenomenon in Parkinson's disease. We report our experience with apomorphine in treating the 'on/off' phenomenon in L-dopa responsive idiopathic Parkinson's disease. Thirteen such patients were commenced on apomorphine infusions. Their mean age was 69 (range 53-80) years and the mean duration of the disease was 15 (range 6-28) years. The clinical response to apomorphine was good in four patients, fair in two, unchanged in five and worse in two. Activities of daily living improved in six, were unchanged in five and worse in two. When the response was poor or showed no change, apomorphine was discontinued. In addition, apomorphine was also discontinued in three patients who had had a fair/good response but suffered side effects of hallucinations, delusions and psychosis, lack of cooperation or found the pump inconvenient. Apomorphine was continued in only three patients out of 13.

Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions.

The efficacy of flecainide acetate in suppressing ventricular premature contractions in 14 patients was evaluated in a double-blind, cross-over, placebo controlled, randomized and balanced study. Each treatment period was 2 weeks followed by a 3-4 d placebo washout period and the study lasted 5 weeks. Flecainide was given in a dose of 200 mg twice daily. A significant reduction in the total number of QRS complexes in a 24 h period was observed during the active compared with placebo treatment (P less than 0.05). In comparison with placebo, flecainide reduced the number of aberrant and premature aberrant QRS complexes (P less than 0.01). The mean suppression rate of aberrant QRS complexes during flecainide treatment was 85.4% and that of premature aberrant complexes was 93.2%. Maximum heart rate measured by 24 h ECG decreased significantly during flecainide therapy (P less than 0.01), although no change occurred with resting heart rate measured clinically or by ECG. Severe dizziness associated with flecainide therapy necessitated withdrawal of 2 patients from the study. A proarrhythmic effect of flecainide, ventricular tachycardia, was observed in one patient.

Effect of flecainide on cardiac output.

The effect of intravenous flecainide (2 mg/kg) on cardiac output was evaluated by a dye dilution method in six healthy nonsmokers. The study was of a double-blind, crossover, placebo-controlled, randomized, and balanced design. Cardiac output, heart rate, and stroke volume were measured 0, 10, 30, 60, 90, 120, 150, 180, and 240 minutes after the beginning of the flecainide infusion. Flecainide reduced cardiac output and stroke volume during the first 90 minutes and heart rate increased during the first 30 minutes after flecainide. Visual analog scales for alertness and dry mouth were determined 0, 10, 60, and 240 minutes after dosing. Alertness was reduced 60 minutes after flecainide, but there was no increase in dryness of the mouth.

The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

The effect of urinary pH on flecainide excretion has been evaluated in six healthy subjects after a single oral dose of 300 mg flecainide administered as the acetate salt. The cumulative urinary excretion of unchanged flecainide under acidic conditions (134.0 +/- 16.1 mg; mean +/- s.e. mean) was significantly higher than under alkaline conditions (22.3 +/- 7.6 mg; mean +/- s.e. mean) (P less than 0.01). Under alkaline conditions, tmax (time to reach peak concentration) was reduced (P less than 0.01), while elimination half-life, AUC(0-32) and AUC(0-infinity) were increased (P less than 0.01).

The effect of a new antiarrhythmic agent, flecainide acetate, on systolic time intervals.

We investigated the effect of flecainide on systolic time intervals in 6 healthy subjects. A randomized, double blind, cross-over study was designed using flecainide (2 mg/kg), propranolol (0.2 mg/kg) or saline. In comparison with placebo, flecainide increased heart rate, diastolic BP, QT-Index, QS2-Index, PEP, and reduced LVET-Index (p less than 0.05). It caused a significant increase in PR interval, QRS duration, and PEP/LVET (p less than 0.01). Propranolol, compared with placebo, decreased heart rate and systolic BP (p less than 0.05). It increased PR interval, PEP, and PEP/LVET ratio (p less than 0.05). In comparison with propranolol, flecainide increased heart rate and QRS duration (p less than 0.01, p less than 0.001 respectively). It increased diastolic BP, PR interval, QS2-Index, PEP, and PEP/LVET ratio, and decreased LVET-Index (p less than 0.05). These changes in STI induced by flecainide may be produced by depression of myocardial contractility. Intraventricular conduction delay may be an additional contributing factor.